IP Library › Granted Patent US 11,629,172
Granted Patent B2
US 11,629,172 · App. 16/721,229 · Granted Apr 18, 2023

Human cytomegalovirus gB polypeptide

Inventors: Philip Ralph Dormitzer (Nyack, NY); Ye Che (Niantic, CT); Xiaoyuan Sherry Chi (Tenafly, NJ); Seungil Han (Mystic, CT); Kyle Paul Heim (Boulder, CO); Thomas Richard Jones (Bluffton, SC); Yuhang Liu (South Glastonbury, CT); Xiayang Qiu (Mystic, CT); Xinzhen Yang (Woodcliff, NJ); Xiaojie Yao (East Lyme, CT); Matthew Curtis Griffor (North Stonington, CT); Jennifer Anne Nicki (Gales Ferry, CT)
Assignee: Pfizer Inc.
C07K14/005A61K39/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,629,172
App. No.
16/721,229
Granted
Apr 18, 2023
Kind
B2
Abstract

The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.

Claims (14)

1. A polypeptide comprising an amino acid sequence set forth in any one of SEQ ID NOs: 2-45 and 47-106.

2. The polypeptide according to claim 1 , wherein the sequence comprises SEQ ID NO: 56.

3. The polypeptide according to claim 1 , wherein the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 57.

4. The polypeptide according to claim 1 , wherein the sequence comprises SEQ ID NO: 58.

5. The polypeptide according to claim 1 , wherein the sequence comprises SEQ ID NO: 75.

6. A polynucleotide encoding a polypeptide comprising an amino acid sequence set forth in any one of SEQ ID Nos: 2-45 and 47-106.

7. A composition comprising a polypeptide of claim 1 and a diluent.

8. The composition according to claim 7 , wherein the composition does not comprise a polypeptide having the amino acid sequence set forth in any one of SEQ ID NO: 59, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 71, SEQ ID NO: 52, SEQ ID NO: 96, and SEQ ID NO: 50.

9. The composition according to claim 7 , further comprising a polypeptide comprising any one amino acid sequence selected from SEQ ID NOS: 211-224.

10. A composition comprising a polynucleotide encoding a polypeptide comprising the sequence selected from any one of SEQ ID Nos: 2-45 and 47-106; and a diluent.

11. The composition according to claim 10 , further comprising a polynucleotide comprising a sequence selected from any one of SEQ ID NOS: 141-210.

12. The composition according to claim 10 , further comprising a polynucleotide comprising a sequence selected from any one of SEQ ID NOS: 224-254.

13. A method of eliciting an immune response in a mammal, comprising administering an effective amount of a composition comprising a polypeptide comprising the sequence set forth in any one of SEQ ID Nos: 2-45 and 47-106; and a diluent.

14. A method of eliciting an immune response in a mammal, comprising administering an effective amount of a composition comprising a polynucleotide encoding a polypeptide comprising the sequence set forth in any one of SEQ ID Nos: 2-45 and 47-106; and a diluent.

Assignments (1)
ASSIGNEE ADDRESS CORRECTION Recorded Mar 20, 2023
From: PFIZER INC.
To: PFIZER INC.
Reel/Frame 063119/0087 →